Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pharmacological Research

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1006/PHRS.1998.0461PMID 10378986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Zafirlukast

  2012cited by this paper
• Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.

  1999cited by this paper
• Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.

  1998cited by this paper
• A Randomized Controlled Trial Comparing Zileuton With Theophylline in Moderate Asthma

  1998cited by this paper
• Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.

  1998cited by this paper
• Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

  1998cited by this paper
• Pharmacological characterization of the cysteinyl‐leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro

  1998cited by this paper
• Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial

  1998cited by this paper
• Inflammation and airway function in asthma: what you see is not necessarily what you get.

  1998cited by this paper
• Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids.

  1998cited by this paper
• The role of leukotriene modifiers in the treatment of asthma.

  1998cited by this paper
• Efficacy and safety of inhaled corticosteroids. New developments.

  1998cited by this paper
• A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group.

  1998cited by this paper
• Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

  1998cited by this paper
• Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

  1998cited by this paper
• Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.

  1998cited by this paper
• Churg-Strauss syndrome associated with zafirlukast.

  1998cited by this paper
• A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.

  1998cited by this paper
• Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

  1998cited by this paper
• Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients.

  1998cited by this paper
• The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.

  1998cited by this paper
• Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast.

  1997cited by this paper
• Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air.

  1997cited by this paper
• Worldwide clinical experience with the first marketed leukotriene receptor antagonist.

  1997cited by this paper
• Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.

  1997cited by this paper
• Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.

  1997cited by this paper
• Montelukast causes prolonged, potent leukotriene D4‐receptor antagonism in the airways of patients with asthma

  1997cited by this paper
• Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.

  1997cited by this paper
• Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005.

  1997cited by this paper
• Are leukotrienes involved in causing bronchial hyperresponsiveness?

  1997cited by this paper
• Dose‐related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene–receptor antagonist, at the end of a once‐daily dosing interval

  1997cited by this paper
• Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.

  1997cited by this paper
• The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.

  1997cited by this paper
• Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.

  1997cited by this paper
• Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

  1997cited by this paper
• Differential regulation of cyclo‐oxygenase‐2 and 5‐lipoxygenase‐activating protein (FLAP) expression by glucocorticoids in monocytic cells

  1997cited by this paper
• Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.

  1997cited by this paper
• The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.

  1997cited by this paper
• Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma.

  1997cited by this paper
• Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.

  1997cited by this paper
• Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist.

  1997cited by this paper
• Challenge studies of a leukotriene receptor antagonist.

  1997cited by this paper
• Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group.

  1997cited by this paper
• Leukotriene Activity Modulation in Asthma

  1997cited by this paper
• Measurements of leukotrienes in the urine: strategies and applications

  1997cited by this paper
• Are leukotrienes involved in causing bronchial hyperresponsiveness

  1997cited by this paper
• Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers.

  1996cited by this paper
• Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.

  1996cited by this paper
• Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.

  1996cited by this paper
• In vivo effect of prednisolone on release of leukotriene B4 from neutrophils from asthmatic patients.

  1996cited by this paper
• Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.

  1996cited by this paper
• Modulators of leukotriene biosynthesis and receptor activation.

  1996cited by this paper
• Urinary leukotriene E4 in the assessment of nocturnal asthma.

  1996cited by this paper
• A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.

  1996cited by this paper
• Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.

  1996cited by this paper
• Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.

  1996cited by this paper
• Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Leukotriene B4 receptor antagonists: Recent clinical developments

  1996cited by this paper
• Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.

  1996cited by this paper
• Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial

  1996cited by this paper
• Discovery of MK-0476, a Potent and Orally Active Leukotriene D4 Receptor Antagonist Devoid of Peroxisomal Enzyme Induction.

  1995cited by this paper
• The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.

  1995cited by this paper
• Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose.

  1995cited by this paper
• Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction

  1995cited by this paper
• Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.

  1995cited by this paper
• Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone.

  1995cited by this paper
• Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.

  1995cited by this paper
• Pharmacokinetics and pharmacodynamics of multiple oral doses of MK‐0591, a 5‐lipoxygenase—activating protein inhibitor

  1994cited by this paper
• Inhibition by a novel peptide leukotriene receptor antagonist ONO‐1078 of airway wall thickening and airway hyperresponsiveness to histamine induced by leukotriene C4 or leukotriene D4 in guinea‐pigs

  1994cited by this paper
• Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma.

  1994cited by this paper
• The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics.

  1994cited by this paper
• Comparison of patients' compliance with prescribed oral and inhaled asthma medications.

  1994cited by this paper
• Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.

  1994cited by this paper
• Influence of leukotriene antagonists on baseline pulmonary function and asthmatic responses.

  1994cited by this paper
• Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.

  1994cited by this paper
• Effect of oral prednisone on airway inflammatory mediators in atopic asthma.

  1994cited by this paper
• Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.

  1994cited by this paper
• Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion.

  1993cited by this paper
• The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.

  1993cited by this paper
• Inhibition of leukotriene D4‐induced bronchoconstriction in subjects with asthma: a concentration‐effect study of ICI 204,219

  1993cited by this paper
• Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects.

  1993cited by this paper
• The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma

  1993cited by this paper
• The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma.

  1993cited by this paper
• Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679.

  1993cited by this paper
• The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

  1993cited by this paper
• Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.

  1993cited by this paper
• Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids.

  1993cited by this paper
• Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219.

  1993cited by this paper
• Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.

  1993cited by this paper
• Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.

  1992cited by this paper
• Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma.

  1992cited by this paper
• Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma.

  1992cited by this paper
• Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo.

  1992cited by this paper
• Urinary leukotriene E4 excretion in exercise-induced asthma.

  1992cited by this paper
• Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist.

  1992cited by this paper
• Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.

  1992cited by this paper
• Early efficacy data with a newer generation of LTD4 antagonists in antiasthma trials: early promise for a single mediator antagonist.

  1992cited by this paper
• Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man.

  1991cited by this paper
• Reversal and prevention of airway response to antigen challenge by the inhaled leukotriene D4 antagonist (L‐648, 051) in patients with atopic asthma

  1991cited by this paper
• Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects.

  1991cited by this paper
• Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses.

  1991cited by this paper

• CYSLTR1 rs320995 (T927C) and GSDMB rs7216389 (G1199A) Gene Polymorphisms in Asthma and Allergic Rhinitis: A Proof-of-Concept Study

  2022cites this paper
• Inhaled corticosteroids’ effects on biomarkers in exhaled breath condensate and blood in patients newly diagnosed with asthma who smoke

  2021cites this paper
• Vegetable dietary pattern may protect mild and persistent allergic rhinitis phenotype depending on genetic risk in school children

  2020cites this paper
• Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.

  2017cites this paper
• N-Acetyltransferase 2 Genotypes Are Associated With Diisocyanate-Induced Asthma

  2015cites this paper
• Efficacy of Ginger in Patients Uncontrolled on Standard Moderate Asthma Treatment

  2012cites this paper
• Role of Leukotriene Modifiers in the Treatment of Asthma

  2012influential citation
• Pathophysiological Role of Leukotrienes in Dermatological Diseases

  2012cites this paper
• Cysteinyl‐leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells

  2011cites this paper
• Early timing of low-dose dexamethasone decreases inflammation in a murine model of eosinophilic airway disease

  2009cites this paper
• Leukotriene D4 up-regulates furin expression through CysLT1 receptor signaling.

  2008cites this paper
• Signaling by the Cysteinyl-Leukotriene Receptor 2

  2008cites this paper
• Endogenous and exogenous glucocorticoid effects in a model of allergic airway inflammation.

  2008cites this paper
• Blocking leukotrienes optimize asthma control: The BLOC survey

  2007influential citation
• CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression.

  2006cites this paper
• Contrôle de l’inflammation bronchique de l’asthme : Pourquoi ? Comment ?

  2005cites this paper
• Effets synergiques et additifs entre les différentes classes d'anti-inflammatoires de l'asthme

  2005cites this paper
• The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?

  2005cites this paper
• Polymorphisms in the 5‐lipoxygenase activating protein (ALOX5AP) gene are not associated with asthma in an Australian population

  2005cites this paper
• The cysteinyl-leukotriene-1 receptor antagonist zafirlukast is a potent secretagogue in rat and human airways.

  2005cites this paper
• [Synergic effects of anti-inflammatory drugs in asthma].

  2004cites this paper
• Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.

  2004cites this paper
• Eicosanoids and Lower Limb Ischemia

  2004cites this paper
• Leukotrienes mediate 5-hydroxytryptamine-induced plasm extravasation in the rat knee joint via CysLT-type receptors

  2004cites this paper
• Effets additifs et synergiques entre les médicaments anti-inflammatoires de l' asthme

  2004cites this paper
• Characterization of Cysteinyl Leukotriene Receptors on Human Saphenous Veins: Antagonist Activity of Montelukast and its Metabolites

  2004cites this paper
• Neurogenic inflammation of the bladder.

  2003cites this paper
• Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites

  2003cites this paper
• Montelukast

  2002cites this paper
• Spotlight on Montelukast in Asthma in Children 2 to 14 Years of Age

  2002cites this paper
• Divergent effect of mometasone on human eosinophil and neutrophil apoptosis.

  2002cites this paper
• Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man.

  2002cites this paper
• in Children 2 to 14 Years of Age

  2002cites this paper
• Induction of a non-allergic inflammation in the human respiratory tract by organic dust

  2001cites this paper
• [Pharmacology of glucocorticoids and ENT pathology].

  2001cites this paper
• Pathophysiological Role of Leukotrienes in Dermatological DiseasesTherapeutic Implications

  2001cites this paper
• Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications.

  2001cites this paper
• The Novel 5-Lipoxygenase Inhibitor ABT-761 Attenuates Cerebral Vasospasm in a Rabbit Model of Subarachnoid Hemorrhage

  2001cites this paper
• Disruption of γ-Glutamyl Leukotrienase Results in Disruption of Leukotriene D4 Synthesis In Vivo and Attenuation of the Acute Inflammatory Response

  2001cites this paper
• Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis.

  2000cites this paper
• Montelukast: a review of its therapeutic potential in persistent asthma.

  2000cites this paper
• Montelukast

  2000cites this paper
• Anti-leucotriènes (3) : leur place dans le traitement de l'asthme

  1999cites this paper